APR - 5 2011

# 510(k) Summary (per 21 CFR 807.92)

# Applicant Contact Information:

Applicant: Instrumentation Laboratory Co.   
Address: 180 Hartwell Road   
Bedford, MA 01730   
Contact Person: Carol Marble, Regulatory Affairs Director Phone Number: 781-861-4467   
Fax Number: 781-861-4207   
Preparation Date: April 5, 2011

Device Trade Names (Products Sold Separately):

HemosIL® LA Positive Control HemosIL® LA Negative Control v.

# Device Regulatory Information:

Positive Control: Class H Product Code: GGN 21 CFR 864.5425   
Negative Control: Class HI Product Code: GIZ 21 CFR 864.5425

# Predicate Devices:

K935254 LAtrol Abnormal Control and LAtrol Normal Control (Manufacturer: American Diagnostica)

# Device Descriptions:

HemosIL LA Positive Control

The LA Positive Control is a lyophilized preparation from human donors exhibiting the presence of anti-phospholipid antibodies with added buffer, which has been determined to be positive for LA in accordance with the Guidelines from ISTH'.

The control assesses the precision and accuracy of Lupus Anticoagulant (LA) tests performed on IL Coagulation Systems using HemosIL LA assays.

HemosIL LA Negative Control

The LA Negative Control is a lyophilized preparation using human citrated platelet-poor plasma to make a Pooled Normal Plasma with added buffer. The guidelines from ISTH', recommends a plateletpoor plasma as a negative control for Lupus Anticoagulant (LA).

The control assesses the precision and accuracy of Lupus Anticoagulant (LA) tests performed on I Coagulation Systems using HemosIL LA assays.

# 510(k) Summary (Cont.)

# Device Intended Uses:

HemosL LA Positive Control: For use as an LA Positive Quality Control of Lupus Anticoagulant assays (HemosL LAC Screen/LAC Confirm; HemosIL Silica Clotting Time) on I Coagulation systems [ACL $\mathrm { T O P ^ { \bullet } }$ Family, ACL ELITE®/ELITE PRO/8/9/100, ACL Futura/ACL Advance, ACL Classic (100-7000)].   
Hemos LA Negative Control: For use as an LA Negative Quality Control of Lupus Anticagulant assays (HemosIL LAC Screen/LAC Confirm; HemosIL Silica Cloting Time) on IL Coagulation systems [ACL $\mathrm { T O P ^ { \otimes } }$ Family, ACL ELITE®/ELITE PRO/8/9/10000, ACL Futura/ACL Advance, ACL Classic (100-7000)].

# Statement of Technological Characteristics of the Device Compared to Predicate Devices:

HemosIL LA Positive Control and HemosIL LA Negative Control are substantially equivalent to LAtrol Abnormal Control and LAtrol Normal Control (K935254).

Substantial Equivalence Comparison Table:   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>New Devices (Sold Separately):HemosIL LA Positive Control andHemosIL LA Negative Control</td><td rowspan=1 colspan=1>Predicate Devices:LAtrol Abnormal Control andLAtrol Normal Control(K935254)</td></tr><tr><td rowspan=1 colspan=1>Intended UseYor</td><td rowspan=1 colspan=1>HemosIL LA Positive Control:For use as an LA Positive QualityControl of Lupus Anticoagulant assays(HemosIL LAC Screen/LAC Confirm;HemosIL Silica Clotting Time) on ILCoagulation systems [ACL TOPFamily, ACL ELITE®/ELITEPRO/8/9/10000, ACL Futura/ACLAdvance, ACL Classic (100-7000)].HemosIL LA Negative Control:For use as an LA Negative QualityControl of Lupus Anticoagulant assays(HemosIL LAC Screen/LAC Confirm;HemosIL Silica Clotting Time) on ILCoagulation systems [ACL TOPFamily, ACL ELITE®/ELITEPRO/8/9/10000, ACL Futura/ACLAdvance, ACL Classic (100-7000)].</td><td rowspan=1 colspan=1>The LAtrol Abnormal Control andLAtrol Normal Control plasmashave been developed for use as partof daily quality control proceduresfor Lupus Anticoagulant (LA)testing.</td></tr><tr><td rowspan=1 colspan=1>Analyte Being Tested</td><td rowspan=1 colspan=1>Lupus Anticoagulant</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized Plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Constituent Material</td><td rowspan=1 colspan=1>•  HemosIL LA Positive Control:Lyophilized preparation from humandonors exhibiting the presence of anti-phospholipid antibodies with addedbuffer.HemosIL LA Negative Control:Lyophilized preparation using humancitrated platelet-poor plasma to make aPooled Normal Plasma with addedbuffer.</td><td rowspan=1 colspan=1>LAtrol Abnormal Control:Lyophilized preparation of aLupus Anticoagulant plasmawith Buffer.LAtrol Normal Control:Lyophilized preparation of amulti-donor Normal plasmapool with Buffer.</td></tr><tr><td rowspan=1 colspan=1>Reconstituted Stability</td><td rowspan=1 colspan=1>24 Hours at 2-8° C</td><td rowspan=1 colspan=1>8 Hours at 2-8° C</td></tr></table>

# Summary Performance Data:

Precision

# Standard:

E05-A2:Evaluation of Precision Performance of Quantitative Measurement Methods, 2nd Edition, 08/20/2004

# Materials:

HemosIL LA Positive Control and HemosIL LA Negative Control (2 Lots of Each Control, with one representative lot shown on the following pages) HemosIL LAC Screen and Confirm (K990302) HemosL Silica Clotting Time  Screen and Confirm (K050221)

Protocol: EY $\bf { N } { = } 8 0$ (2 replicates per run/2 runs per day/20 days) using two lots of each control level with two different LA assays\* per instrument platform. The data from a representative lo  o  o s

$\scriptstyle * _ { \mathrm { N O T E } } . . .$ Only HemosIL LAC Screen/LAC Confirm was tested on the ACL Classic models (ACL $3 0 0 +$ , ACL 3000 and ACL 6000). There is no test application on these models for HemosIL Silica Clotting Time.

# Representative IL Coagulation Systems:

• ACL TOP Family Members: TOP (base model) and 500 CTS   
: ACL 10000   
: ACL Advance   
: ACL $3 0 0 +$   
: ACL 3000   
• ACL 6000

# Specifications:

• HemosIL LA Negative Control: Within run and Total $\leq 6 \%$ CV • HemosIL LA Negative Control: Within run and Total $\leq 6 \%$ CV

# Conclusion:

All results were well within specification for both lots of controls tested.

# 510(k) Summary (Cont.)

# Summary Performance Data (Cont.):

# Precision

Instrument: ACL TOP Reagent: HemosIL LAC Screen/Confirm

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>LACConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>32.1</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>30.8</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=2 colspan=1>LAC Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>32.9</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>56.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>HemosHLA..Positive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>1:64</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.5</td></tr></table>

Instrument: ACL TOP Reagent: HemosIL Silica Clotting Time (Screen/Confirm)

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>SCTConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>35.7</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>37.3</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=2 colspan=1>SCT Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>33.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>75.0</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>2.15</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.2</td></tr></table>

# 510(k) Summary (Cont.)

# Summary Performance Data (Cont.):

# Precision

Instrument: ACL TOP 500 CTS Reagent: HemosIL LAC Screen/Confirm

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>LACConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>31.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>32.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=2 colspan=1>LAC Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>33.1</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>56.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>0.96</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>57r$i&#x27;HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>1.58</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.8</td></tr></table>

Instrument: ACL TOP 500 CTS Reagent: HemosIL Silica Clotting Time (Screen/Confirm)   

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>SCTConfirm</td><td rowspan=1 colspan=1>HemoslL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>35.7</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>36.8</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=2 colspan=1>SCT Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>32.7</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>74.1   </td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>2.20</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.3</td></tr></table>

# 510(k) Summary (Cont.)

# Summary Performance Data (Cont.):

# Precision

Instrument: ACL 10000 Reagent: HemosIL LAC Screen/Confirm

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>LACConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>30.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>31.9</td><td rowspan=1 colspan=1>0.8&#x27;</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=2 colspan=1>LAC Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>33.8</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>58.1</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>7HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>3.0</td></tr></table>

Instrument: ACL 10000 Reagent: HemosIL Silica Clotting Time (Screen/Confirm)   

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>SCTConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>34.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>*N1190681</td><td rowspan=1 colspan=1>33.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=2 colspan=1>SCT Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>32.0</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>69.5</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.6    A</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>2.22</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.2</td></tr></table>

# 510(k) Summary (Cont.)

Summary Performance Data (Cont.):

# Precision

Instrument: ACL Advance Reagent: HemosIL LAC Screen/Confirm

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>LACConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>28.7</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>30.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=2 colspan=1>LAC Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>32.0</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>53.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>71HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>1.58</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>.2.8</td><td rowspan=1 colspan=1>3.3</td></tr></table>

Instrument: ACL Advance Reagent: HemosIL Silica Clotting Time (Screen/Confirm)

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>SCTConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>31.8</td><td rowspan=1 colspan=1>1.9 .</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>32.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=2 colspan=1>SCT Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>32.2</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>69.2</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>2.12</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>4.2</td></tr></table>

# 510(k) Summary (Cont.)

Summary Performance Data (Cont.):

# Precision

Instrument: ACL 6000 Reagent: HemosIL LAC Screen/Confirm

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>LACConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>30.9</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>32.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=2 colspan=1>LAC Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>32.9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>56.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>${a}$HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>1.66</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.8</td></tr></table>

Instrument: ACL 3000 Reagent: HemosIL LAC Sereen/Confirm

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>LACConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>30.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>33.8</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=2 colspan=1>LAC Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>32.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>×0.7</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>57.1</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>1.64</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.6</td></tr></table>

# 510(k) Summary (Cont.)

# Summary Performance Data (Cont.):

# Precision

Instrument: ACL $\pmb { 3 0 0 + }$ Reagent: HemosIL LAC Screen/Confirm

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>ControlLot No.</td><td rowspan=1 colspan=1>GrandMean(s)</td><td rowspan=1 colspan=1>CV%Within Run</td><td rowspan=1 colspan=1>CV%BetweenRun</td><td rowspan=1 colspan=1>CV%Total</td></tr><tr><td rowspan=2 colspan=1>LACConfirm</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>31.9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>32.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=2 colspan=1>LAC Screen</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>34.0</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>Hemoslb LA.Positive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>58.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=2 colspan=1>NormalizedRatio,</td><td rowspan=1 colspan=1>HemosIL LANegative Control</td><td rowspan=1 colspan=1>N1190682</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.9</td></tr><tr><td rowspan=1 colspan=1>HemosIL LAPositive Control</td><td rowspan=1 colspan=1>N1190681</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.6</td></tr></table>

Instrumentation Laboratory Co. c/o Ms. Carol Marble Regulatory Affairs Director 180 Hartwell Road Bedford, MA 01730

# APR 0 5 2011

Re: k102552 Trade/Device Name: HemosIL $^ \mathrm { \textregistered }$ LA Positive Control and HemosIL $\textsuperscript { \textregistered }$ LA Negative Control Regulation Number: 21 CFR 864.5425 Regulation Name: Multipurpose system for in vitro coagulation studies Regulatory Class: Class II Product Code: GGC, GIZ, GGN Dated: March 29, 2011 Received: March 30, 2011

Dear Ms. Marble:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket

notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
htip://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/f5a538aa86411e621ab798b66f770ee2506da896ca9cb64b04b67cf703936931.jpg)

![](images/12197f743f11ac88952aee8328ea2ba988da48d2f203479404daaf2a1095dcf9.jpg)

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

# Indications for Use Statement

510(k) Number (fkown):/02552

Device Name:

HemosIL LA Positive ControlHemosIL® LA Negative Control

# Indications for Use:

HemosIL LA Positive Control

For use as an LA Positive Quality Control of Lupus Anticoagulant assays (HemosIL LAC Screen/LAC Confirm; HemosI Silica Clotting Tim on I Coagulation systems [ACL TOP® Family; ACL ELITE/ELITE PRO/8/9/1000; ACL Futura/ACL Advance; ACL Classic (100- 7000).

The control assesses the precision and accuracy of LupusAntiagulant (LA) tests perorme n IL Coagulation Systems using HemosIL LA assays.

HemosIL LA Negative Control

For use as an LA Negative Quality Control of Lupus Anticoagulant assays (HemosIL LAC Sceen/AC Conm Hemo Sl Clot  Caguat t ACL TO Family; ACL ELITE®/ELITE PRO/8/9/1000; ACL Futura/ACL Advance; ACL Classic (100- 7000)].

Th contro assesses he precision and accuracy f Lupus Anticagulant (LA) tests performen IL Coagulation Systems using HemosIL LA assays.

SikS Division Sign-Off Office of In Vitro Diagnostic-Device Evaluation and Safety

510(k) 102552